Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series

Table 1 Patient demographics

Patient	Gender	Age (years)	Follow-up (months)	Localization	Denosumab preoperative	Denosumab postoperative
1	F	30	36	Distal humerus	Yes	Yes
2	M	31	43	Femoral head	No	Yes
3	F	65	21	Distal tibia	Yes	Yes
4	M	51	33	Distal radius	No	Yes
5	M	72	32	Distal femur	No	Yes
6	M	32	17	Distal femur	Yes	Yes
7	F	16	33	Patella	Yes	No
8	F	19	41	Distal tibia	Yes	No
9	M	62	31	Metacarpal bone	Yes	No
10	F	21	31	Proximal tibia	Yes	No
11	F	15	49	Proximal tibia	Yes	Yes
12	M	62	27	Distal radius	Yes	Yes
13	M	29	19	Distal femur	Yes	Yes
14	F	40	17	Sacrum	Yes	Yes
15	M	27	21	Proximal tibia	No	Yes
16	F	27	14	Proximal fibula	Yes	Yes
17	M	27	14	Proximal radius	Yes	Yes
18	F	44	15	Proximal fibula	Yes	No
19	F	30	13	Distal femur	Yes	Yes
20	M	31	13	Distal femur	Yes	No
21	M	25	9	Distal tibia	Yes	Yes
22	M	46	14	Distal femur	No	Yes
23	M	22	10	Calcaneus	No	Yes
24	F	37	10	Distal femur	No	Yes
25	F	23	13	Iliac wing	Yes	No

ISSN: 1477-7819